Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2025.427 | A Phase II trial on Fezolinetant for vasomotor symptoms in men receiving androgen deprivation therapy (ADT) for prostate cancer (Fez-Cap) | Prof. NG Chi Fai |
| 2006.215 | A Phase II Trial of VELCADE in Patients with Metastatic or Locally Recurrent Nasopharyngeal Carcinoma | MA Brigette |
| 2007.367 | A Phase II Trial of Sunitinib (SU11248) in Multiple Myeloma | Prof. Chan T.C. Anthony |
| 2013.338 | A phase II trial of PEG-BCT-100 as the second-line therapy following sorafenib in patients with advanced hepatocellular carcinoma | Dr. CHAN Stephen Lam |
| 2013.159 | A phase II trial of neoadjuvant imatinib for large gastric GIST in Asia | Professor Ng Enders Kwok Wai |
| 2010.422 | A Phase II trial of BAY 86-9766 plus sorafenib as a first line systemic treatment for hepatocellular carcinoma (HCC) | Prof. Yeo Winnie |
| 2006.149 | A Phase II Trial of 17-Allylamiogeldanamycin (17AAG) in Advanced Medullary and Differentitated Thyroid Carcinoma | MA Buig Yue Brigette |
| 2009.010 | A Phase II Study to Evaluate the Effectiveness of Acupuncture in Treating Chemotherapy Induced Peripheral Neuropathy (CIPN) | Prof. Mok Tony |
| 2008.410 | A Phase II Study on the Therapeutics Effects of Acupuncture for Neurogenic Dysphagia | Ms Chan Sze Ling |
| 2003.352 | A Phase II Study of Triapine and Gemcitabine as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer in Patients who had Prior Gemcitabine with Evaluation of the Effect of Triapine_ on Gemcitabine Pharmacokinetics and Cellular Uptake in Peripheral Mononuclear Cells | Prof. Ma Buig Yue Brigette |
| 2010.359 | A Phase II Study of Transarterial Chemoembolization and Axitinib for the Treatment of Unresectable Hepatocellular Carcinoma | Prof. CHAN Stephen Lam |
| 2002.169 | A Phase II Study Of The Efficacy And Safety of Irinotecan in Combination With Capecitabine As First Line Chemotherapy in Asia Subjects With Inoperable Hepatocellular Carcinoma | Dr. Mok Tony |
| 2008.125 | A Phase II Study of Stereotactic Body Radiation Therapy (SBRT) under Active Breathing Control for Primary Lung Cancer and Lung Metastases | Dr. Tsang Wai Kong |
| 2002.155 | A Phase II Study of Sequential Administration of Irinotecan and Cisplatin Combination Followed by Docetaxel in Treatment of Advanced Non-small Cell Lung Cancer | Prof. Mok Tony |
| 2011.176 | A phase II study of orally administered BEZ235 monotherapy in patients with hormone receptor positive, HER2 negative, metastatic breast cancer, with or without PI3K activated pathway | Dr. Ho Wing Ming |
| 2005.408 | A Phase II Study of Hormonal Therapy and Docetaxel and Prednisolone in Patients with Hormone-Treatment Na_ve Metastatic Prostate Adenocarcinoma | Dr. Ng Chi Fai |
| 2008.141 | A Phase II Study of GW 786034 (Pazopanib) in Advanced Thyroid Cancer | Prof. MA Brigette |
| 2007.198 | A Phase II Study of Concurrent Chemoradiotherapy Using Three-Dimensional Conformal Radiotherapy (3D-CRT) or Intensity-Modulated Radiation Therapy (IMRT) + Bevacizumab (BV) for Locally or Regionally Advanced Nasopharyngeal Cancer | Prof. CHAN Anthony T. C. |
| 2005.416 | A Phase II Study of Concurrent Cetuximab, Cisplatin and Radiotherapy in the Treatment of Advanced Nasopharyngeal Carcinoma | Prof. Ma Buig Yue Brigette |
| 2008.512 | A Phase II Single Arm, Multi-Centre Study of Bevacizumab (Avastin_) Pre- and Post- Transarterial Chemoembolisation (TACE) Treatment for Localised Unresectable Hepatocellular Carcinoma (HCC) | Prof. Lai Bo San Paul |
| 2008.092 | A Phase II Safety and Efficacy Study with the VEGF Receptor Tyrosine Kinase Inhibitor GW786034 in Patients with Metastatic Urothelial Cancer | Dr HO Wing Ming |
| 2015.002 | A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride versus placebo when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects with bone metastases treated with hormonal treatment background therapy | Dr. SUEN Joyce |
| 2005.020 | A Phase II Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled, Dose-Ranging, Parallel Group Study of the Safety and Efficacy of The Oral Neurokinin-1 Receptor Antagonist, GW679769 When Administered as a Daily Doses of 50mg, 100mg and 150mg Oral Tablets in Combination with Ondansetron Hydrochloride and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Subjects Receiving Highly Emetogenic Cisplatin-based Chemotherapy | Prof. Yeo Winnie |
| 2019.694 | A phase II clinical trial to study the efficacy of cabozantinib in patients with hepatocellular carcinoma refractory to checkpoint inhibitors |
Dr. CHAN Stephen Lam 陳林 |
| 2023.684 | A phase II clinical study to evaluate the safety, efficacy, and pharmacokinetics of RBD1016 injection in participants with chronic hepatitis B | Prof. WONG Grace Lai Hung |
| 2020.445 | A Phase II CCCG-ALL Multi-center Trial of Dasatinib in Combination with Intensive Induction Therapy for Children with First Relapsed T-cell Acute Lymphoblastic Leukemia |
Prof. LI Chi Kong 李志光 |
| 2019.352 | A Phase Ib/IIa, Single Ascending Dose Study of the Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients with Type 2 Diabetes Mellitus | Dr. CHOW Elaine Yee Kwan |
| 2016.172 | A phase Ib/II, open-label, multi-center study of INC280 in combination with PDR001 or PDR001 single agent in advanced hepatocellular carcinoma |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2013.294 | A phase Ib/II, open-label study of LJM716 in combination with BYL719 compared to taxane or irinotecan in patients with previously treated esophageal squamous cell carcinoma | Prof. MA Brigette Buig Yue |
| 2017.357 | A Phase Ib/II, open label, multicenter study of MCS110 in combination with PDR001 in patients with advanced malignancies |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2015.389 | A Phase Ib/II, Multicentre, Open Label, Randomised Study of BI 836845 in Combination with Enzalutamide, versus Enzalutamide alone, in Metastatic Castration-Resistant Prostate Cancer (CRPC) Following Disease Progression on Docetaxel-Based Chemotherapy and Abiraterone |
Dr. HO Wing Ming 何永明醫生 |
| 2019.652 | A phase Ib/II, multicenter open-label study of CS1001 in combination with regorafenib in patients with advanced or refractory solid tumors | Dr. LOONG Herbert Ho Fung |
| 2020.626 | A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2024.593 | A Phase Ib/II Dose Finding Study Assessing Safety and Efficacy of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination with Carboplatin, Etoposide and Atezolizumab in Induction and with Atezolizumab in Maintenance Phase | Prof. MOK Tony Shu Kam |
| 2019.327 | A Phase Ib, open-label, multi-center study to characterize the safety, tolerability, and preliminary efficacy of TNO155 in combination with spartalizumab or ribociclib in selected malignancies |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2017.452 | A Phase Ib, Open Label, Multiple Ascending Dose, Pilot Study to Assess the Safety, Preliminary Efficacy and Pharmacokinetics of Subcutaneously Administered APL-2 in Subjects with Paroxysmal Nocturnal Hemoglobinuria (PNH). – PADDOCK – |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2018.553 | A phase Ib, open label, multi-center study to characterize the safety, tolerability and preliminary efficacy of EGF816 in combination with selected targeted agents in EGFR mutant NSCLC |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2018.436 | A Phase Ib, multicenter, open-label dose escalation and expansion platform study of select immunotherapy combinations in adult patients with triple negative breast cancer |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2013.392 | A phase Ib trial of LEE011 in combination with everolimus (RAD001) and exemestane in the treatment of postmenopausal women with hormone receptor positive HER2 negative locally advanced or metastatic breast cancer | Prof. MA Brigette Buig Yue |
| 2014.357 | A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) ADMINISTERED WITH ERLOTINIB OR ALECTINIB IN PATIENTS WITH ADVANCED NON−SMALL CELL LUNG CANCER | Prof. MA Brigette Buig Yue |
| 2017.049 | A phase Ib study of PDR001 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2014.662 | A phase Ib dose-finding study of BYL719 plus everolimus and BYL719 plus everolimus plus exemestane in patients with advanced solid tumors, with dose-expansion cohorts in renal cell cancer (RCC), pancreatic neuroendocrine tumors (pNETs), and advanced breast cancer (BC) patients. | Prof. MA Brigette Buig Yue |
| 2012.315 | A phase Ib dose escalation/randomized phase II, multicenter, open-label study of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma | Prof. MA Brigette Buig Yue |
| 2019.555 | A Phase Ia/Ib, Open-Label, Dose-Escalation and Dose-Expansion Study of the Anti-CTLA-4 Monoclonal Antibody CS1002 as Monotherapy and in Combination with Anti-PD-1 Monoclonal Antibody CS1003 in Subjects with Advanced Solid Tumors |
Dr. CHAN Stephen Lam 陳林 |
| 2024.647 | A Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0022 Monotherapy and in Combination with Anti-cancer Agents in Participants with Tumours Harbouring a KRASG12D Mutation (ALAFOSS-01) | Prof. MA Brigette Buig Yue |
| 2009.588 | A Phase I/Iia, Open-Label, Crossover, Dose-Escalation, and Multi-Center Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc in Previously Treated Patients with Severe Hemphilia A | Dr. Wong Raymond Siu Ming |
| 2016.625 | A Phase I/IIa Study of BMS 986148, a Mesothelin Directed Antibody Drug Conjugate, in Subjects with Select Advanced Solid Tumors |
Dr. LOONG Herbert 龍浩鋒 |
| 2009.186 | A Phase I/IIa Safety and Pharmacokinetic Study of Intravenous FIXFc Administration to Previously Treated Hemophilia B Patients | Prof. Cheng Gregory |
| 2009.275 | A Phase I/II, Open-label, Multicentre Study to Assess the Safety & Tolerability, and Pharmacokinetics of AZD8055 in Asian Patients with Advanced Stage Hepatocellular Carcinoma (HCC) and with Mild or Moderate Hepatic Impairment | Prof. Ma Brigette |
| 2025.605 | A Phase I/II, Open-label, Multicenter Study of ALE.P03 (Claudin-1 Targeted Antibody-drug Conjugate) as a Monotherapy in Adult Patients with Selected Advanced or Metastatic CLDN1+ Solid Tumors | Prof. CHAN Stephen Lam |
Page 266 of 289.